title: Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits.
abstract: The authors compared the ability of a single dose of the proenzyme single-chain urokinase (scuPA), low-molecular-weight urokinase, tissue plasminogen activator (tPA), or a mutant site-inactive scuPA to resolve intrapleural loculations at 72 to 96 hours after tetracycline-induced pleural injury in rabbits. Both scuPA and tPA reversed loculations at 96 hours after injury P < or = .001, whereas low-molecular-weight urokinase and the scuPA mutant were ineffective. scuPA and tPA generated inhibitor complexes, induced fibrinolytic activity, and quenched plasminogen activator-1 activity in pleural fluids. The authors conclude that scuPA reverses loculations as effectively as tPA at clinically applied intrapleural doses, whereas low-molecular-weight urokinase was ineffective.
authors.affiliation: Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas 75708, USA. steven.idell@uthct.edu
authors.forename: Steven
authors.initials: S
authors.lastname: Idell
authors.forename: Ali
authors.initials: A
authors.lastname: Azghani
authors.forename: Shande
authors.initials: S
authors.lastname: Chen
authors.forename: Kathy
authors.initials: K
authors.lastname: Koenig
authors.forename: Andrew
authors.initials: A
authors.lastname: Mazar
authors.forename: Lalitha
authors.initials: L
authors.lastname: Kodandapani
authors.forename: Khalil
authors.initials: K
authors.lastname: Bdeir
authors.forename: Douglas
authors.initials: D
authors.lastname: Cines
authors.forename: Irina
authors.initials: I
authors.lastname: Kulikovskaya
authors.forename: Timothy
authors.initials: T
authors.lastname: Allen
mesh_terms: D000818:Animals; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D010994:Pleura / Q000737:chemistry / Q000166:cytology / Q000187:drug effects*; D010996:Pleural Effusion / Q000517:prevention & control; D010998:Pleurisy / Q000517:prevention & control; D018700:Pleurodesis; D011817:Rabbits; D013752:Tetracycline / Q000633:toxicity*; D000267:Tissue Adhesions / Q000517:prevention & control; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; C036309:fibrin fragment D; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D013752:Tetracycline